Stockscreener 앱 받기
183.21
0.26%
-1.22
전일 마감가:
$181.99
열려 있는:
$180.7
하루 거래량:
257.48K
Relative Volume:
0.32
시가총액:
$3.86B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-19.98
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
-8.94%
1개월 성능:
+233.79%
6개월 성능:
+351.08%
1년 성능:
+159.23%
1일 변동 폭
$178.98
$186.72
1주일 범위
$167.03
$206.71
52주 변동 폭
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
183.39 | 4.53B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.28 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.38 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.69 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.92 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
PRAX Secures FDA Alignment on Relutrigine Program - GuruFocus
Praxis (NASDAQ: PRAX) Q4 2025 interim may back 2026 relutrigine NDA in SCN2A & SCN8A - Stock Titan
Is Praxis Precision Medicines Inc. stock a contrarian buyMarket Performance Report & Daily Stock Momentum Reports - newser.com
Published on: 2025-11-04 03:14:53 - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Is a relief rally coming for Praxis Precision Medicines Inc. holdersQuarterly Profit Review & Safe Investment Capital Preservation Plans - newser.com
How analysts rate Praxis Precision Medicines Inc. stock today2025 Fundamental Recap & Low Risk Growth Stock Ideas - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Is Praxis Precision Medicines Inc. stock near bottom after decline2025 Buyback Activity & AI Enhanced Trading Alerts - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com
How institutional buying supports Praxis Precision Medicines Inc. stockJuly 2025 Sector Moves & Verified Short-Term Plans - newser.com
Published on: 2025-11-03 06:18:43 - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatWeekly Risk Summary & High Yield Equity Trading Tips - newser.com
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Bull Run & Reliable Volume Spike Trade Alerts - newser.com
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-03 03:06:20 - newser.com
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Published on: 2025-11-02 22:52:57 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsTrade Analysis Summary & Long-Term Capital Growth Strategies - newser.com
Praxis Precision Medicines prices $525M public offering - MSN
Published on: 2025-11-01 00:59:14 - newser.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $206.36 By Investing.com - Investing.com Australia
Published on: 2025-10-31 03:19:21 - newser.com
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $206.36 - Investing.com
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? - sharewise.com
Published on: 2025-10-29 21:58:45 - newser.com
What’s Happening With Praxis Stock? - Trefis
Does Positive Phase 3 Data for Ulixacaltamide Transform the Outlook for Praxis Precision Medicines (PRAX)? - Sahm
Published on: 2025-10-29 03:41:05 - newser.com
Praxis Precision Medicines’ PRAX-562 Trial: A Potential Game-Changer for Epileptic Encephalopathies - TipRanks
Praxis Precision Medicines (PRAX) Price Target Increased by 153.57% to 258.64 - Nasdaq
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Option Exercise |
56.94 |
7,583 |
431,776 |
18,540 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
1.02%
0.57%
자본화:
|
볼륨(24시간):